We demonstrated that CHRM4/IFNA17-activated prostate cancer cells might interact with M2-type TAMs to promote NED and immune checkpoint pathways in prostate cancer cells, contributing to the development of an immunosuppressive TME and NEPC. Here, CHRM4 is linked to Familial prostate cancer.